Your browser doesn't support javascript.
loading
Simple and rapid high-throughput assay to identify HSV-1 ICP0 transactivation inhibitors.
Ly, Cindy Y; Yu, Chunmiao; McDonald, Peter R; Roy, Anuradha; Johnson, David K; Davido, David J.
Afiliación
  • Ly CY; Department of Molecular Biosciences, The University of Kansas, Lawrence, KS, 66045, USA.
  • Yu C; Department of Molecular Biosciences, The University of Kansas, Lawrence, KS, 66045, USA.
  • McDonald PR; High Throughput Screening Laboratory, The University of Kansas, Lawrence, KS, 66047, USA.
  • Roy A; High Throughput Screening Laboratory, The University of Kansas, Lawrence, KS, 66047, USA.
  • Johnson DK; Computational Chemical Biology Core, The University of Kansas, Lawrence, KS, 66047, USA.
  • Davido DJ; Department of Molecular Biosciences, The University of Kansas, Lawrence, KS, 66045, USA. Electronic address: ddavido@ku.edu.
Antiviral Res ; 194: 105160, 2021 10.
Article en En | MEDLINE | ID: mdl-34384824
Herpes simplex virus 1 (HSV-1) is a ubiquitous virus that results in lifelong infections due to its ability to cycle between lytic replication and latency. As an obligate intracellular pathogen, HSV-1 exploits host cellular factors to replicate and aid in its life cycle. HSV-1 expresses infected cell protein 0 (ICP0), an immediate-early regulator, to stimulate the transcription of all classes of viral genes via its E3 ubiquitin ligase activity. Here we report an automated, inexpensive, and rapid high-throughput approach to examine the effects of small molecule compounds on ICP0 transactivator function in cells. Two HSV-1 reporter viruses, KOS6ß (wt) and dlx3.1-6ß (ICP0-null mutant), were used to monitor ICP0 transactivation activity through the HSV-1 ICP6 promoter:lacz expression cassette. A ≥10-fold difference in ß-galactosidase activity was observed in cells infected with KOS6ß compared to dlx3.1-6ß, demonstrating that ICP0 potently transactivates the ICP6 promoter. We established the robustness and reproducibility with a Z'-factor score of ≥0.69, an important criterium for high-throughput analyses. Approximately 19,000 structurally diverse compounds were screened and 76 potential inhibitors of the HSV-1 transactivator ICP0 were identified. We expect this assay will aid in the discovery of novel inhibitors and tools against HSV-1 ICP0. Using well-annotated compounds could identify potential novel factors and pathways that interact with ICP0 to promote HSV-1 gene expression.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Activación Transcripcional / Proteínas Inmediatas-Precoces / Herpesvirus Humano 1 / Ubiquitina-Proteína Ligasas / Ensayos Analíticos de Alto Rendimiento Tipo de estudio: Prognostic_studies Idioma: En Revista: Antiviral Res Año: 2021 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Países Bajos

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Activación Transcripcional / Proteínas Inmediatas-Precoces / Herpesvirus Humano 1 / Ubiquitina-Proteína Ligasas / Ensayos Analíticos de Alto Rendimiento Tipo de estudio: Prognostic_studies Idioma: En Revista: Antiviral Res Año: 2021 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Países Bajos